Akhu Therapeutics, Inc. has acquired a license for key technology, MC5R blockers, to treat depression faster and more effectively than current therapies do. This exclusive, worldwide license was acquired from the University of Arizona and Texas A&M University. It also enables us to use this same technology to develop medicine to treat anxiety.
This technology involves an extensive series of state-of-the-art peptide compounds that are designed to block the melanocortin-5 receptor (MC5R). Therefore, it works differently than antidepressants (e.g., SSRIs) and anxiolytics (e.g., benzodiazepines). In our preclinical studies, this mechanism of action is more effective than those of antidepressants, and it and works in a fraction of the time. To view the full press release, (click here). To view an up-to-date list of media sites for the press release, (click here).